SynCo, Versartis Extend VRS-859 Manufacturing Partnership
Versartis said that VRS-317, a once monthly form of human growth hormone for the treatment of children and adults with growth hormone deficiency. Earlier, SynCo Bio Partners (SynCo)
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.
Abraxane is a solvent-free chemotherapy treatment option for metastatic breast cancer which was developed using Abraxis BioScience’s proprietary nab technology platform. Abraxis BioScience said that it has granted